ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.084,70
1,14%
S&P 500
5.744,80
0,39%
US Dollar vs BRL
5,43763
-0,69%
Bitcoin
65.178,84
3,24%
Brent Oil
71,065
-2,90%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) Notícias

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VNDA
DataHoraFonteTítuloCódigoCompanhia
19/09/202409:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
19/09/202408:00PR Newswire (US)FDA Declines to Approve Vanda's Marketing Application for Tradipitant in GastroparesisNASDAQ:VNDAVanda Pharmaceuticals Inc
11/09/202418:00PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
04/09/202418:13PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
29/08/202417:30PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
08/08/202408:47Edgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
01/08/202408:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
31/07/202417:01PR Newswire (US)Vanda Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
29/07/202418:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
29/07/202418:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
26/07/202410:19PR Newswire (US)Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
01/07/202409:01PR Newswire (US)Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and ApotexNASDAQ:VNDAVanda Pharmaceuticals Inc
19/06/202421:48PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
13/06/202411:02PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
06/06/202410:24PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.NASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202418:20PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
30/05/202417:48PR Newswire (US)Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®NASDAQ:VNDAVanda Pharmaceuticals Inc
29/05/202415:17PR Newswire (US)Vanda Pharmaceuticals Announces Presentations at SLEEP 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202417:46PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202417:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202417:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VNDAVanda Pharmaceuticals Inc
15/05/202409:45PR Newswire (US)Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessNASDAQ:VNDAVanda Pharmaceuticals Inc
13/05/202417:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202417:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202417:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202409:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
22/04/202420:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202411:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202410:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202411:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VNDA

Seu Histórico Recente

NASDAQ
TBLD
Thomburg Income Builder ...
USOTC
NROM
Noble Romans (QB)
COIN
JOYSSUSD
Joys Digital
EU
UTI
Amundi ST EU Utilities
COIN
DEXTFUST
DEXTF Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados